Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NTLA
STRONG SELLIntellia Therapeutics, Inc. · Healthcare · United States · $1.5B · Avg Vol: $63M/d
COMPANY DESCRIPTION
Intellia Therapeutics, Inc. is a leading clinical-stage genome editing company focused on developing curative medicines using its proprietary CRISPR/Cas9 technology platform. The company is a pioneer in both in vivo and ex vivo gene editing approaches, targeting severe genetic diseases and oncology indications. Its competitive moat stems from its foundational intellectual property and expertise in precision gene editing, positioning it at the forefront of genetic medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.1M | 36.3M | 57.9M | 67.7M | 9.1% | 66.1M | 59.2M | — | -12.5% |
| EPS | -6.16 | -5.42 | -5.25 | -3.81 | — | -3.38 | -3.14 | -1.76 | — |
| Shares | 87.1M | 93.0M | 102.0M | 116.3M | +33.5% | 139.7M | — | — | — |
| Debt | 130.7M | 115.3M | 210.2M | 93.3M | -10.6% | 80.5M | — | — | — |
| Equity | 1.2B | 1.1B | 872.0M | 671.4M | -18.4% | — | — | — | — |
| Op CF | -333.3M | -394.1M | -348.9M | -394.7M | — | -363.2M | — | — | — |
| Inv CF | 160.3M | -31.3M | 125.6M | 228.0M | — | — | — | — | — |
| Fin CF | 583.0M | 130.3M | 185.7M | 131.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NTLA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc.(you) | $1.5B | 15 | STRONG SELL |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 10 | STRONG SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 18 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 17 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 16 | STRONG SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| AKTS | Aktis Oncology, Inc. | $1.3B | 10 | STRONG SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| VOR | Vor Biopharma Inc. | $1.0B | 14 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 18 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%